Novel Biomarkers in Cardiovascular Disease: A Review

摘要: BACKGROUND: The investigation of novel circulating serum and plasma biomarkers in patients with cardiovascular disease has been accelerating at a remarkable pace. New markers or tests are often presented too early to the medical profession, potentially leading overuse and, thus, extra burden costs patients, healthcare industry, economy. challenge for clinicians researchers is how optimally apply existing new markers/tests. CONTENT: Biomarkers biological parameters that can be objectively measured quantified as indicators normal biologic processes, pathogenic responses therapeutic intervention. Typically thought process screening, diagnosing, monitoring tools, may also used determine susceptibility eligibility specific therapies. Cardiac protein components cell structures released into circulation when myocardial injury occurs. They play pivotal role diagnosis, risk stratification, treatment chest pain suspected acute coronary syndrome (ACS) well those exacerbations heart failure. SUMMARY: Active brought forward an increasingly large number candidate but few have withstood test time become integrated contemporary clinical care because their readily apparent diagnostic, prognostic, and/or utility. With regard more biomarkers, careful needed appropriate target populations discovery validation, criteria sort out contenders from pretenders. KEYWORDS: biomarker, disease, atherosclerosis, infarction, failure, prognosis